We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TOL:NYSEToll Brothers, Inc. Analysis

Data as of 2026-09-01 - not real-time

$140.21

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Toll Brothers, Inc. trades at $140.21, with its moving averages tangled rather than clearly stacked — a neutral trend structure. It has lost 4.7% over the past 30 days. Relative strength is 39.6 — approaching oversold — and the MACD signal is bearish. The recent range runs from support at $140.05 up to resistance at $155.97.
The shares look undervalued at 11.3 times earnings, though no sector average was available for comparison. Analyst price targets sit 22.6% above the current price. Revenue is contracting at 9.7% on a 11.1% profit margin. The 0.72% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 6 — elevated. With 30-day volatility of 34.2%, a beta of 1.25 and a maximum drawdown of 25.3%, position sizing matters here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 4/10 long-term conviction.

Top Market Events

Homebuilding company Toll Brothers NYSE:TOL reported Q2 CY2026 results beating Wall Street’s revenue expectations,...Homebuilding company Toll Brothers NYSE:TOL reported Q2 CY2026 results , but sales fell by 9.Seeking Alpha14dToll Brothers Q3 earnings beat even as affordability still weighs on housing marketToll Brothers TOL...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Trading below the 200-day average of 144.29
  • MACD momentum is negative
  • Maximum drawdown of 25.3%

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Trading below the 200-day average of 144.29
  • Analyst targets imply +22.6% versus the current price
  • MACD momentum is negative

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • Analyst targets imply +22.6% versus the current price
  • Revenue contracting at -9.7%
  • P/E ratio of 11.3

Key Metrics & Analysis

Financial Health

Revenue Growth-9.70%
Profit Margin11.14%
P/E Ratio11.3
ROE14.39%
ROA6.90%
Debt/Equity34.10
P/B Ratio1.5
Op. Cash Flow$1.2B
Free Cash Flow$557.7M

Technical Analysis

TrendNeutral
RSI39.6
Support$140.05
Resistance$155.97
MA 20$148.05
MA 50$150.98
MA 200$144.29
MACDBearish
VolumeStable
Fear & Greed Index92.25

Valuation

Fair Value$56.70
Target Price$171.87
Upside/Downside22.58%
GradeUndervalued
TypeBlend
Dividend Yield0.72%

Risk Assessment

Beta1.25
Volatility34.25%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.